CY1108381T1 - PHARMACEUTICAL COMPOSITIONS CONTAINING OXAPENEMO-3-CARBOXYLIC ACIDS - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING OXAPENEMO-3-CARBOXYLIC ACIDS

Info

Publication number
CY1108381T1
CY1108381T1 CY20081101073T CY081101073T CY1108381T1 CY 1108381 T1 CY1108381 T1 CY 1108381T1 CY 20081101073 T CY20081101073 T CY 20081101073T CY 081101073 T CY081101073 T CY 081101073T CY 1108381 T1 CY1108381 T1 CY 1108381T1
Authority
CY
Cyprus
Prior art keywords
oxapenemo
pharmaceutical compositions
carboxylic acids
compositions containing
bipolar ion
Prior art date
Application number
CY20081101073T
Other languages
Greek (el)
Inventor
Hans Rudolf Pfaendler
Iain Nelson Simpson
Original Assignee
Amura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00309207A external-priority patent/EP1199077A1/en
Priority claimed from GB0105766A external-priority patent/GB0105766D0/en
Priority claimed from EP01974489A external-priority patent/EP1326607B1/en
Application filed by Amura Limited filed Critical Amura Limited
Publication of CY1108381T1 publication Critical patent/CY1108381T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D503/10—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Μια ένωση οξαπενέμης η οποία είναι διπολικό ιόν, ή είναι ικανή να σχηματίσει διπολικό ιόν του τύπου la ή lb: (la), (lb) στους οποίους R είναι ένα C1-C8 αλκύλιο με διακλαδισμένη ή ευθεία αλυσίδα που περιλαμβάνει έναν πρωτονιωμένο βασικό υποκατάστατη. Οι ενώσεις χρησιμοποιούνται ιδιαιτέρως ως υψηλής βιοδιαθεσιμότητας αναστολείς της β-λακταμάσης.An oxapenem compound which is a bipolar ion, or capable of forming a bipolar ion of the formula la or lb: (la), (lb) in which R is a C1-C8 branched or straight chain alkyl comprising a protonated basic substituent. The compounds are particularly used as high bioavailability of β-lactamase inhibitors.

CY20081101073T 2000-10-19 2008-09-29 PHARMACEUTICAL COMPOSITIONS CONTAINING OXAPENEMO-3-CARBOXYLIC ACIDS CY1108381T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00309207A EP1199077A1 (en) 2000-10-19 2000-10-19 Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers
GB0105766A GB0105766D0 (en) 2001-03-08 2001-03-08 Orally active compounds
GB0119165A GB2369358A (en) 2000-10-19 2001-08-06 Oxapenems and pharmaceutical compositions thereof
EP01974489A EP1326607B1 (en) 2000-10-19 2001-10-11 Pharmaceutical compositions containing oxapenem-3-carboxilic acids

Publications (1)

Publication Number Publication Date
CY1108381T1 true CY1108381T1 (en) 2014-02-12

Family

ID=26073338

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101073T CY1108381T1 (en) 2000-10-19 2008-09-29 PHARMACEUTICAL COMPOSITIONS CONTAINING OXAPENEMO-3-CARBOXYLIC ACIDS

Country Status (5)

Country Link
KR (1) KR100814802B1 (en)
CY (1) CY1108381T1 (en)
GB (1) GB2369358A (en)
IL (1) IL155183A (en)
PT (1) PT1326607E (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100620310B1 (en) * 2005-02-22 2006-09-11 손세호 A vacuum cleaner and fly exterminater

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3725375A1 (en) * 1987-07-31 1989-02-09 Bayer Ag STABLE OXAPENEM-3-CARBONSAEURES
DE3833693A1 (en) * 1988-10-04 1990-04-05 Bayer Ag STABLE OXAPENEM-3-CARBONSAEURES AND THEIR USE AS SS-LACTAMATE HEMMER
DE4142423A1 (en) * 1991-12-20 1993-06-24 Pfaendler Hans Rudolf ((LS) -HYDROXYALKYL) OXAPENEM-3-CARBON ACIDS AND THEIR USE AS BETALACTAMATE HEMMER

Also Published As

Publication number Publication date
PT1326607E (en) 2008-09-11
KR100814802B1 (en) 2008-03-19
KR20030070011A (en) 2003-08-27
IL155183A (en) 2009-12-24
GB0119165D0 (en) 2001-09-26
GB2369358A (en) 2002-05-29

Similar Documents

Publication Publication Date Title
CY1110104T1 (en) Piperazine Derivatives as NSAIDs
EP1490371A4 (en) Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
DK0931788T3 (en) metalloprotease
BRPI0206433B8 (en) compound, pharmaceutical composition, and use of a compound
CY1107634T1 (en) PHARMACEUTICAL COMPOSITION
RS49673B (en) Nitric oxide synthase inhibitors
CY1106247T1 (en) THIOPHEN- AND THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS
CY1106358T1 (en) NEW BICYCLIC INHIBITORS OF HORMONE-SENSITIVE LIPASE
CY1107839T1 (en) HYDROXAMIC PRODUCTS USEFUL AS DESTINATING SUSPENDS
NO20041493L (en) Chemical connections.
DK1206467T3 (en) N-heterocyclic derivatives as NOS inhibitors
NO20054787D0 (en) Indene derivatives as pharmaceuticals
EA200000826A1 (en) HALIDATED DERIVATIVES OF AMIDINOMOMINO ACIDS APPLICABLE AS NO-SYNTHASE INHIBITORS
EA200000804A1 (en) META-AZACLIC COMPOUNDS OF AMINOBENZOIC ACID AND THEIR DERIVATIVES, WHICH ARE INTEGRINE INHIBITORS
PE20010751A1 (en) QUINOLIN-2-ONA AS INHIBITORS OF PROTEINS RESISTANT TO MULTIPLE DRUGS
ATE278661T1 (en) ANTHRANILIC ACID DERIVATIVES
ATE235462T1 (en) METALLOPROTEINASE INHIBITORS
SE0103710D0 (en) Compounds
CY1111606T1 (en) DIVISION PROCEDURE FOR (R) - (-) - 2-HYDROXY-2- (2-CHLOROPHENYL) ACETIC ACID
NO20061316L (en) Imidazopyndin derivatives as inducible NO synthase inhibitors
BRPI0411308A8 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING A COMPOUND, AND USE OF A COMPOUND
CY1108381T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING OXAPENEMO-3-CARBOXYLIC ACIDS
EA200101230A1 (en) NEW INHIBITORS OF METALLOPROTEASIS, THEIR METHOD OF OBTAINING AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
DK0937043T3 (en) Substituted tetrahydropyridine derivatives, processes for their preparation and pharmaceutical compositions containing these derivatives
CR8456A (en) INHIBITORS HETEROCICLIL AMINO 11- BETA- HYDROXIESTEROID DEHYDROGENASE TYPE 1